2017-05-19

Camurus and Braeburn Pharmaceuticals announce positive Top-line results from long-term Phase 3 safety study of CAM2038

New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorder.

On 2 May 2017 Camurus (NASDAQ STO:CAMX) and Braeburn Pharmaceuticals announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder.

Latest news

2024-04-16

Research donation from Sandberg Development for increased knowledge about water

In April 2024, Sandberg Development donated 100 million Swedish kronor, distributed over a 10-year period, to Malmö…

2024-02-01

Sandberg Development growing its incubator with investment in start-up PluvioFlow

Sandberg Development is a family-owned investment company that contributes to growth and social value through active…

2023-06-29

Sandberg Development becomes largest owner of water technology company Watersprint

The Malmö-based family-owned investment company, Sandberg Development, is now the largest owner of water technology…

2023-06-07

Sandberg Development starts its own incubator – first company in will be Xocchiali AB

Sandberg Development is a family-owned investment company that contributes to growth and social value through active…

2023-05-24

Sandberg Development makes its first investment outside Sweden – becomes part-owner in Italian dishwasher manufacturer Silanos

The family-owned, Malmö-based investment company Sandberg Development has become a new owner of the family-owned, It…